You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Low Cost, Quantitative, Chemical Specific Device for Illicit Drug Detection

    SBC: MKS Technology            Topic: NIDA

    DESCRIPTION provided by applicant This proposal will assess the quantitative capabilities of surface enhanced Raman scattering SERS detection of cocaine and marijuana metabolites in urine samples Combining low cost instrumentation and novel chemical sensing provides an innovative new approach for diagnosing illicit drug use Current methods use a colorimetric indicator to screen specimens fo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Reduced gluten cereal grains

    SBC: Arcadia Biosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Synactix Pharmaceuticals I-Corps Application

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.

    SBC: PROMUTECH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory

    SBC: Botanisol LLC            Topic: R

    DESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government